BRCA2 and neoplasm: As continued work with berzosertib ensues, it will be important to consider biomarker-driven approaches that target tumours harbouring ATM truncating mutations or ATM protein loss, TP53 mutations, BRCA1 or BRCA2 mutations, or other alterations conferring homologous recombination repair deficiency.